Primary Care Clinics in Paonia, CO Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 Dcmh West Elk Walk-in Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 218 Grand Ave, Paonia, CO 81428 Phone: 970-527-2100 Fax: 970-527-2107 |
North Fork Medical Clinic Pc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 225 Minnesota Ave, Paonia, CO 81428 Phone: 970-527-4103 Fax: 970-527-5171 |
Brain Reintegration Center Llc Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 225 Minnesota Ave, Paonia, CO 81428 Phone: 541-647-0644 |
News Archive
MDI to advance Detect-Ready MRSA Panel with $1.9M Series B recapitalization financing
Molecular Detection Inc., a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has completed a $1.9 million Series B recapitalization financing.
Celgene's first-quarter non-GAAP total revenue up 31% to $789 million
Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.
dLife Healthcare Solutions teams up with Welltok to deliver innovative diabetes solutions to people
dLife Healthcare Solutions announced today that it teamed up with Welltok to bring its proven diabetes behavior change program to the CaféWell Health Optimization Platform, which enables population health managers – health plans, employers and at-risk providers – to guide and incentivize consumers to optimize their health.
Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.
› Verified 5 days ago